Vivos Inc
Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. The company develops an yttrium-90 based precision radionuclide therapy device; RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the tre… Read more
Vivos Inc (RDGL) - Total Assets
Latest total assets as of September 2025: $2.30 Million USD
Based on the latest financial reports, Vivos Inc (RDGL) holds total assets worth $2.30 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Vivos Inc - Total Assets Trend (2014–2024)
This chart illustrates how Vivos Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Vivos Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Vivos Inc's total assets of $2.30 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 99.1% |
| Accounts Receivable | $10.33K | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Vivos Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vivos Inc's current assets represent 100.0% of total assets in 2024, an increase from 33.6% in 2014.
- Cash Position: Cash and equivalents constituted 99.1% of total assets in 2024, up from 0.2% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 40.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Vivos Inc Competitors by Total Assets
Key competitors of Vivos Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Vivos Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Vivos Inc generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Vivos Inc is currently not profitable relative to its asset base.
Vivos Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 20.37 | 25.49 | 1.04 |
| Quick Ratio | 19.81 | 25.49 | 1.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.18 Million | $ 1.20 Million | $ 32.03K |
Vivos Inc - Advanced Valuation Insights
This section examines the relationship between Vivos Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 14.39 |
| Latest Market Cap to Assets Ratio | 14.64 |
| Asset Growth Rate (YoY) | 38.7% |
| Total Assets | $2.23 Million |
| Market Capitalization | $32.69 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Vivos Inc's assets at a significant premium ( 14.64x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Vivos Inc's assets grew by 38.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Vivos Inc (2014–2024)
The table below shows the annual total assets of Vivos Inc from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $2.23 Million | +38.71% |
| 2023-12-31 | $1.61 Million | -7.61% |
| 2022-12-31 | $1.74 Million | +6.64% |
| 2021-12-31 | $1.63 Million | +74.32% |
| 2020-12-31 | $937.54K | +2036.94% |
| 2019-12-31 | $43.87K | +166.12% |
| 2018-12-31 | $16.49K | +5.03% |
| 2017-12-31 | $15.70K | -62.62% |
| 2016-12-31 | $42.00K | -83.48% |
| 2015-12-31 | $254.26K | +180.88% |
| 2014-12-31 | $90.52K | -- |